Oleiferasaponin A₂, a Novel Saponin from Camellia oleifera Abel. Seeds, Inhibits Lipid Accumulation of HepG2 Cells Through Regulating Fatty Acid Metabolism.
Tai-Mei DiShao-Lan YangFeng-Yu DuLei ZhaoXiao-Han LiTao XiaXin-Fu ZhangPublished in: Molecules (Basel, Switzerland) (2018)
A new triterpenoid saponin, named oleiferasaponin A₂, was isolated and identified from Camellia oleifera defatted seeds. Oleiferasaponin A₂ exhibited anti-hyperlipidemic activity on HepG2 cell lines. Further study of the hypolipidemic mechanism showed that oleiferasaponin A₂ inhibited fatty acid synthesis by significantly down-regulating the expression of SREBP-1c, FAS and FAS protein, while dramatically promoting fatty acid β-oxidation by up-regulating the expression of ACOX-1, CPT-1 and ACOX-1 protein. Our results demonstrate that the oleiferasaponin A₂ possesses potential medicinal value for hyperlipidemia treatment.